In the article cited above, the content in Table 9.2 regarding clinical considerations for the class of medications glucagon-like peptide 1 receptor agonists (GLP1-RAs) has been amended to reflect counseling patients about potential for ileus for all medications in this class.
The original content for clinical considerations for GLP1-RAs appeared as follows:
“Counsel patients about potential for ileus (semaglutide SQ)”
The revised content for clinical considerations for GLP1-RAs now reads:
“Counsel patients about potential for ileus”
The online version of Section 9 (https://doi.org/10.2337/dc24-S009) has been updated with the revised text.
A complete list of members of the American Diabetes Association Professional Practice Committee can be found at https://doi.org/10.2337/dc24-SINT.